Navigation Links
Omeros Corporation Reports First Quarter 2011 Financial Results
Date:5/10/2011

SEATTLE, May 10, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2011.

Financial ResultsTotal operating expenses for the three months ended March 31, 2011 were $7.7 million compared to $6.8 million for the same periods in 2010. The increase in operating expense was primarily due to increased clinical trial activities and additional employee costs. For the three months ended March 31, 2011, Omeros reported a net loss of $6.5 million, or $0.30 per share. During the same period in 2010, Omeros reported a net loss of $6.7 million, or $0.31 per share. At March 31, 2011, Omeros had cash, cash equivalents and short-term investments of $43.6 million.  

"The first quarter included several significant events for Omeros, most notably the announcement that our OMS103HP Phase 3 ACL program did not meet its prespecified primary endpoints," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "While this setback delays OMS103HP's commercialization opportunity, the meniscectomy indication for the drug remains viable and, based on strong Phase 2 data, Phase 3 preparations are underway. We also recently reported positive results from our OMS302 Phase 2b, full-factorial OMS302 cataract trial and are submitting a request to the FDA for an end-of-Phase-2 meeting. We are evaluating our multiple options and will soon finalize our clinical plans for the remainder of 2011."

Recent Highlights

  • Announced that Omeros obtained an exclusive license to novel antifibrinolytic agents for the control of surgical and traumatic bleeding.  Research on these agents was published in the February 11,
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
    2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
    3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
    4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
    5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
    6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
    7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
    8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
    9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
    10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
    11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... PARK, N.J. , July 30, 2015  Unichem ... voluntarily recalling one lot of Hydrochlorothiazide tablets 25 mg ... been initiated as a precautionary measure due to the ... of the product. The risk associated ... Hydrochlorothiazide tablet is the increased probability of experiencing Clopidogrel,s ...
    (Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced the appointment ... Warburg Pincus LLC, to the Amgen Board of Directors. ... and the deep, global experience he brings in the ... Bradway , chairman and chief executive officer of Amgen. "Fred,s breadth ... well." Mr. Hassan has been Partner and Managing ...
    (Date:7/30/2015)... , July 30, 2015  Growth of the ... as they bring former prescription users to the OTC ... Kline forecasts robust Rx-to-OTC switch activity over the ... emerging along with many new brands entering the market ... over the next five years (even those with low ...
    Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
    ... More and the Lalela Project announced today their new joint ... international celebrities are taking to the African airwaves to leverage ... message about malaria.   NightWatch is an interactive ... text messaging (SMS) to remind people to sleep under their ...
    ... YORK, Nov. 9, 2010 Reportlinker.com announces that a ... Proteomics - Technologies, Markets and Companies ... SummaryThis report describes and evaluates the proteomic technologies that ... diagnostics and practice of medicine in the post-genomic era ...
    Cached Medicine Technology:World-Renowned Singer Youssou NDour Launches NightWatch Program 2Reportlinker Adds Proteomics - Technologies, Markets and Companies 2Reportlinker Adds Proteomics - Technologies, Markets and Companies 3Reportlinker Adds Proteomics - Technologies, Markets and Companies 4Reportlinker Adds Proteomics - Technologies, Markets and Companies 5Reportlinker Adds Proteomics - Technologies, Markets and Companies 6Reportlinker Adds Proteomics - Technologies, Markets and Companies 7Reportlinker Adds Proteomics - Technologies, Markets and Companies 8Reportlinker Adds Proteomics - Technologies, Markets and Companies 9Reportlinker Adds Proteomics - Technologies, Markets and Companies 10Reportlinker Adds Proteomics - Technologies, Markets and Companies 11Reportlinker Adds Proteomics - Technologies, Markets and Companies 12Reportlinker Adds Proteomics - Technologies, Markets and Companies 13Reportlinker Adds Proteomics - Technologies, Markets and Companies 14Reportlinker Adds Proteomics - Technologies, Markets and Companies 15Reportlinker Adds Proteomics - Technologies, Markets and Companies 16Reportlinker Adds Proteomics - Technologies, Markets and Companies 17Reportlinker Adds Proteomics - Technologies, Markets and Companies 18Reportlinker Adds Proteomics - Technologies, Markets and Companies 19Reportlinker Adds Proteomics - Technologies, Markets and Companies 20
    (Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, ... LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper ... care providers understand the benefits of using medication management technologies . ...
    (Date:7/31/2015)... McLean, VA (PRWEB) , ... July 31, 2015 , ... ... solution at OSEHRA 2015. , What is HITaaS? Health IT as a Service (HITaaS) ... (IaaS) and software as a service (SaaS). , HITaaS manages all aspects ...
    (Date:7/31/2015)... ... 31, 2015 , ... Physical therapy for knee osteoarthritis is an important ... It keeps the patient from doing what they want or need to do. The patient ... using the stairs. The patient's exercise regime may be limited by the pain in their ...
    (Date:7/31/2015)... ... , ... New Energy Works Timberframers invites the public to join their timber ... from 9am – 12pm. Timber frame raisings are special, celebrating both craft ... the culmination of months of effort, planning, fundraising, and dreaming takes shape. , ...
    (Date:7/31/2015)... ... ... The Radiology Business Management Association’s 2015 Fall Educational Conference ... Care: A View From Capitol Hill” on Sunday, Sept. 27, 2015, in Austin, Tex. ... has a special understanding of the real world impact of health care policy issues,” ...
    Breaking Medicine News(10 mins):Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3
    ... frozen ready meals including 20 Asda own brand, 4 Sainsbury’s ... may contain small pieces of glass. Customers are also being ... ,The products came from Rye Valley Foods in Carrickmacross, a ... the country's biggest food processors. The company said pieces of ...
    ... group from Los Angeles has pressed upon Viagra manufacturers to ... pushes the drug’s use as a recreational drug. ... by gay and bisexual men who are also patronizing methamphetamine, ... risks. The AIDS Healthcare Foundation is especially worried that this ...
    ... after being administered DPT (diphtheria, pertussis and tetanus) injection Saturday. ... ,According to official sources, the deaths took place ... km from here. Twelve children have been admitted to Ara ... programme was launched for children below one year of age. ...
    ... Breast and Bowel Project (NSABP) B-33 study, presented ... showed that// postmenopausal women with hormone receptor-positive breast ... tamoxifen were 56% less likely to have a ... placebo (P=0.004). ,“Aromasin provided patients with ...
    ... The prescription for an anti-smoking pill Zyban, given by a ... ,Smokers who were residents of Glasgow, were trying to ... pill. This was mistakenly read as Viagra due to a ... Greater Glasgow and Clyde said , due to an error ...
    ... that women treated for ovarian cancer are at increased ... their tumor cells have high// levels of a binding ... death, both hallmarks of malignancy. ,“Now there’s ... tissue removed during surgery might identify women most at ...
    Cached Medicine News:Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 2Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 3Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 4Health News:'Clumping' Protein Linked to Return of Ovarian Cancer 2
    Slightly curved 10 mm jaws and serrated cross action handle with polished finish. Overall length 4.6 inches....
    Hartman Mosquito forceps, straight, 3.5"....
    Curved 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 3.9 inches...
    Shafts angled 45 degrees with 10 mm jaws. Serrated handle with polished finish. Crisscross serrated jaws. Most popular size or model....
    Medicine Products: